The short answer: A single biologic can carry a five-figure price tag and a prior authorization to match. Immunology and allergy practices protect that revenue by treating the front end of the revenue cycle as carefully as the clinical decision: verifying benefits before the drug is ordered, securing prior authorization, documenting medical necessity in the language payers expect, and tying every dose to the correct J-code and unit count. Advantum Health builds revenue cycle management around that discipline, so specialty-drug claims stay clean from order to payment.
Why high-dollar specialty claims demand front-end discipline
Immunology and allergy practices run on some of the most expensive, most scrutinized therapies in medicine. The average annual cost of a first-line biologic for plaque psoriasis reached $47,125 in 2021, more than double the $21,236 it cost in 2007, according to research published in JAMA Dermatology. Inflammatory-disorder drugs are now the single largest category of specialty drug spend, ahead of oncology.
Most of these therapies move through a buy-and-bill model. The practice purchases the drug, administers it, then bills the payer after the fact. The practice fronts the cost. That changes what a denial means. A stalled claim on a $40,000 infusion is not a paperwork problem. It is working capital sitting in a refrigerator. One unpaid specialty claim can erase the margin on dozens of routine visits.
The payer knows the dollar figure too. High-cost drugs draw the most aggressive utilization management in the industry, which is why the front end carries the weight.
The revenue cycle steps that keep specialty-drug claims clean
Protecting these claims is a sequence, not a single safeguard. Each step closes a gap the next one depends on.
Verify benefits before the drug is ordered. Confirm active coverage, the patient’s specialty-drug benefit and any step-therapy requirement before anyone places the order. Buy-and-bill leaves no room to discover a coverage problem after the vial is open.
Secure prior authorization, and document it precisely. Prior authorization is the rule, not the exception, for biologics. Physicians now complete an average of 40 prior authorizations a week, and nearly one in three say requests are often or always denied, according to the American Medical Association. An authorization approved for one drug, dose or site of care does not cover a different one. Match the authorization to exactly what will be administered.
Document medical necessity in the language payers expect. Payers approve against published criteria: confirmed diagnosis, failed prior therapies, dosing within label. Documentation that does not speak to those criteria invites a denial even when the care is sound. The clinical record has to map to the payer’s policy, not just the clinical reality.
Code the J-code and units correctly. Specialty drugs are billed with HCPCS J-codes in units defined by the code descriptor. A dose-to-unit mismatch is one of the fastest ways to stall a five-figure claim. Drug wastage must be reported with the correct modifier, and many payers require the National Drug Code on the claim line.
Reconcile what was purchased against what was billed. Buy-and-bill only works when inventory, administration and billing reconcile to the unit. A gap between the drug acquired and the drug billed is lost revenue or a compliance exposure, sometimes both.
Common mistakes that put five-figure claims at risk
The errors that sink specialty claims are predictable, which is the good news. Up to 90 percent of claim denials are preventable, and most trace to the front end.
The recurring culprits: a J-code billed with the wrong unit count, an authorization that does not match the administered dose, clinical notes that miss the payer’s medical-necessity criteria, unreported or mis-modified drug wastage, and denials left to age past the filing deadline. Reworking a single denied claim costs $25 to $118 depending on complexity, by HFMA and MGMA estimates, and a large share of denied claims are never reworked at all. On a routine visit, that is an annoyance. On a five-figure infusion, it is a material hit to the month. (See our guide to healthcare revenue cycle management.)
A checklist for practice administrators
Before any specialty drug is administered, confirm the team can answer yes to each:
- Benefits and the specialty-drug benefit are verified, with any step-therapy requirement identified.
- Prior authorization is on file and matches the exact drug, dose and site of care to be administered.
- Clinical documentation maps to the payer’s published medical-necessity criteria.
- The J-code, unit count and any required National Drug Code are confirmed against the dose.
- A wastage modifier is applied when applicable.
- Drug purchased reconciles to drug billed.
- Denials are worked within the payer’s filing window, not after.
How Advantum Health protects specialty-drug revenue
Advantum Health builds the front-end discipline that keeps specialty-drug claims clean from order to payment. That means benefits verification and prior authorization support before the drug is ordered, documentation and coding aligned to payer policy, and denial prevention that catches the unit mismatch or the authorization gap before the claim goes out, not after it comes back. For immunology and allergy practices running on buy-and-bill economics, that is the difference between revenue earned and revenue chased.
See how Advantum Health helps specialty practices protect high-dollar claims.